Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile

Core Insights - Celldex announced multiple presentations of Phase 2 clinical trials for barzolvolimab at the 2026 AAAAI Annual Meeting, focusing on chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) [1][2] Group 1: Clinical Trial Presentations - New data from the Phase 2 ColdU and SD Open Label Extension (OLE) will be presented, indicating that retreatment with barzolvolimab results in rapid improvement in urticaria control after symptom recurrence [2] - The presentations include: - Phase 2 ColdU and SD Study: "Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria" on February 27, 2026 [2] - Phase 2 CSU Study: "Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria" on February 27, 2026 [2] - Phase 2 ColdU and SD Study: "Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria" on March 1, 2026 [2] Group 2: Barzolvolimab Overview - Barzolvolimab is a humanized monoclonal antibody with a novel mechanism of action targeting mast cells by binding to a unique part of the KIT receptor, which is critical for mast cell function and survival [3] - The drug shows significant potential as a first-in-class treatment for CSU, ColdU, and SD, based on data from robust Phase 2 studies [3] - Barzolvolimab is currently undergoing Phase 3 studies for CSU and ColdU/SD, as well as Phase 2 studies for prurigo nodularis (PN) and atopic dermatitis (AD) [3] Group 3: Company Background - Celldex is focused on pioneering new therapies in immunology, particularly antibody-based treatments that engage the human immune system to address allergic, inflammatory, and autoimmune disorders [4]